Screener
Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Interest Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeOperating.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Share-based compensation | (13,653) | (9,997) | (24,249) | (17,833) |
| Other segment items: | ||||
| Amortization of intangibles | (8,097) | (8,258) | (16,194) | (16,515) |
| Depreciation of property and equipment | (118) | (264) | (237) | (777) |
| Interest income | 7,298 | 1,621 | 13,953 | 3,392 |
| Interest expense | (1,748) | (1,153) | (3,495) | (2,020) |
| Other * | 1,133 | (24,729) | (50,030) | (96,811) |
| Net income (loss) | $48,508 | $4,847 | $35,163 | $(37,604) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — interest income of $7.3M in Q2 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income increased by 350.2% year-over-year, from $1.62M to $7.3M.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income has grown at a 88.3% compound annual growth rate (CAGR), from $2.05M to $13.66M.
- What does development and licensing of biopharmaceutical assets — interest income mean?
- This metric captures the interest earned on cash balances, short-term investments, and other interest-bearing assets held by the development and licensing segment. It reflects the segment's ability to generate passive returns from its liquidity position. This income contributes to the overall financial health and self-funding capability of the business unit.
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude